Medical Disclaimer
FDA-cleared indication
In the United States, EXOMIND is intended for the treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode.
Off-label use
Any use outside of that indication is considered off-label and is offered on a cash-pay basis, based on provider judgment and emerging research. Off-label uses are not FDA-cleared indications.
Conditions such as anxiety, stress, OCD, binge eating, cravings, focus, sleep, and cognitive performance are not presented on this website as U.S. FDA-cleared EXOMIND indications. Where we discuss them, we label the use as off-label.
Research and investigational topics
Some areas of brain stimulation remain under active study. Where research is ongoing, we say so, and we do not present preliminary findings as established outcomes. We do not publish medical statistics without a cited source.
No promises
Individual results vary. TMS is not a cure, and no outcome is guaranteed. This page is patient education, not medical advice.
Never start, stop, or change a medication based on information from a website. Medication decisions should always be made with your prescribing clinician.
Crisis situations
If you or someone you know is in immediate danger or experiencing a mental health crisis, call or text 988 or call 911.